Scil Technology GmbH

Development of protein-based products (protein-coated products) for orthopaedic and dental tissue regeneration

Scil Technology is a Holding GmbH. Together with its subsidiaries, the company devlops solutions for therapy and diagnosis. The company was founded in 1999 by Dr. Stefan Engelhorn and Dr. Günter Schumacher as Scil Group. The subsidiary, Scil Proteins, is located in Halle/Saale (Germany) and is focused on developing and manufacturing proteins.

Weishui Weiser, PhD, Managing Director
Christian Nafe, VP Finance
Carola Dony, PhD, CSO
Volker Lang, PhD, VP Corporate Development
Andreas Schütz, PhD, Director Technical Product Development
Roland Seidl, PhD, Director Pharmaceutical Quality

Fraunhoferstraße 15
82152 Martinsried
Germany
Phone: +49-89-85651800
Fax: +49-89-85651818

Scil covers the complete development chain from pharmaceutical, preclinical and clinical development through pharmaceutical technology and quality to regulatory affairs. Scil is developing products that contain growth factors in a tailored matrix of biomaterials that maintain the native structure and enhance the biological activity of the recombinant protein and admit a controlled release of the protein to the tissue. The products are tested by cell assays, animal models and clinical trials and can be manufactured on a commercial aseptic scale. Development pipeline: LAX-101 is an oral drug containing ethyl-icosapent as the active compound for the treatment of Huntington´s disease, a neurodegenerative disease of the brain. This product is currently in the pre-registration phase and the application for marketing authorisation has been submitted to the European agency by Laxdale Ltd., a corporate partner of Scil.

The biomaterial MD05 is developed for bone regeneration and augmentation in the maxillofacial area, e.g. sinus floor augmentation prior to dental implant installation. It contains the bone growth-inducing protein rhGDF-5, which is coated onto a synthetic carrier (beta-tricalcium phosphate). MD06 is a protein coated medical device developed for the implantation into alveolar bone for the reconstruction of artificial or degenerative dental defects. MD06 is also coated with the growth and differentiation factor rhGDF-5. Thus, the dental implant improves and accelerates its osseointegration. The efficacy of MD06 is currently being tested in a preclinical pharmacodynamic study using an appropriate animal model. MD07, which is currently in the research phase, is a biomaterial to be developed for bone repair in the maxillofacial area. The product also contains the bone growth-inducing protein rhGDF-5, which is coated onto a synthetic porous calcium phosphate-based carrier. A protein-based product to be developed for regeneration of bone and soft tissue in periodontal disease, a biomaterial developed for spinal fusion procedures and a product for cartilage regeneration are currently in the research phase.

ST03A is a biodegradable implant for the treatment of osteochondral defects, e.g. in knee injuries. It is a combination of the cartilage growth factor rhCD-RAP and a carrier matrix that allows controlled release of the growth factor to the defect site. ST03B is considered to have a regenerative effect on injured cartilage due to stimulatory effects of the growth factor, and it is also expected to have an inhibitory effect on inflammatory processes associated with osteoarthritis.

Recently, ST01, a ceramic-based osteoinductive, biodegradable bone graft substitute coated with a recombinant human bone morphogenic protein (BMP) variant, has revealed superior efficacy to autologous bone in an in vivo preclinical study for posterolateral interbody spinal fusion.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.